MAPT and Alzheimer disease: These limitations highlight a critical gap: the multifactorial nature of AD cannot be effectively addressed by monotherapies, underscoring the urgent need for multi-targeted strategies capable of simultaneously modulating tau pathology, neuroinflammation, and oxidative stress [9].